Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it will

feature handheld robotics and digital solutions for hip, knee and shoulder in addition to

innovative trauma and extremities products during the American Academy of Orthopaedic Surgeons

(AAOS) Annual Meeting in New Orleans this week. Some of the company's latest Orthopaedics

advancements and highlighted technologies include:

Handheld Robotics: Optimizing and Personalizing Surgery

As the leader in handheld robotics, the CORI^◊ Surgical System delivers a digital surgery

ecosystem–spanning solutions from advanced pre-operative planning and a connected post-operative

data management solution. The entire robotics ecosystem is designed to amplify the surgeon

experience and expertise and has shown improvements in accuracy and patient outcomes in joint arthroplasty.¹,²

Smith+Nephew's CORIOGRAPH^◊ Pre-Op Planning and Modeling Services enables optimization of handheld

robotic knee and shoulder* arthroplasty and computer guided hip – further personalizing surgery for

both surgeons and their patients. CORIOGRAPH Pre-Op Planning and Modeling Services + CORI Surgical

System supports several image modalities - allowing for a new dimension of pre-operative planning

for each individual patient - and supporting the intra-operative surgical workflow.

In the booth at AAOS, Smith+Nephew will have a motion capture lounge demonstrating how 3-D modeling

of patient motion is important in planning implant position and advanced simulated activities of

daily living.

*CORI XT is required for shoulder application

CORI SHOULDER Robotic Shoulder Arthroplasty with the AETOS^◊ Shoulder System: Differentiated

Technology for Personalized Care

In the fast-growing shoulder market, the CORI SHOULDER Platform is well positioned to meet the unmet

needs of surgeons who demand both accuracy and procedural efficiency. The system is specifically

optimized for use with the AETOS Shoulder System. It features the CORI Handheld Robotic Platform

technology and supports robotic preparation of both humeral and glenoid execution for shoulder

arthroplasty.

Smith+Nephew advances robotic shoulder arthroplasty with a complete, handheld solution that

supports seamless integration and workflow efficiencies for shoulder arthroplasty.³ The procedure

represents a significant leap forward in the shoulder arthroplasty space, perfectly suited for the

constraints of the anatomy and supported by a portable footprint for flexibility in the hospital or

ASC.

Last week, the first ever CORI SHOULDER Robotic Shoulder Arthroplasty cases were completed,

performed by a surgical team at Duke Health led by Dr. Christopher Klifto. To learn more, please

visit the CORI SHOULDER website or see a live demo of CORI SHOULDER Robotic Shoulder Arthroplasty

at AAOS in Booth #839.

Advanced Implant Science

Get the latest clinical data and insights on our flagship implant options for hip, knee and

shoulder arthroplasty including recent additions to our portfolio such as LEGION^◊ Total Knee Medial

Stabilized System, CATALYSTEM^◊ Primary Hip System and the AETOS Shoulder System stemless option.

Trauma Advancements

From reduction to fixation, the EVOS^◊ LARGE & PERIPROSTHETIC Plating System has evolved to give

surgeons stability and flexibility with one screw design for threaded locking, and variable-angle

locking and compatibility with the EVOS Cabling System. We will also be expanding the EVOS

portfolio this year with the launch of the EVOS PELVIC System.

TRIGEN^◊ MAX Tibia Nailing System is the only system to give trauma surgeons the choice of

side-specific (right and left) nails for anatomic screw trajectories, which help to optimize

fragment fixation and minimize soft tissue irritation with headless and low-profile screw

options.⁴,⁵ Come visit Smith+Nephew at Booth #839 and hear about the expansion of TRIGEN MAX Tibia

this year.

Smith+Nephew has also recently signed distribution agreements with SI-BONE, focused on their

innovative iFuse TORQ portfolio for pelvic fractures and RMR Ortho for the A'TOMIC™ Nitinol

Fixation System, a compression fixation option for trauma cases.

ASC Portfolio: Expanded Enterprise Offering

At the ASC suite, Smith+Nephew will provide customers with a preview of our expanded enterprise ASC

offering—an end-to-end solution designed to support both de novo ASC development and the

modernization of existing facilities. This comprehensive model enables customers to finance,

design, build, equip, and optimize their centers through one coordinated, streamlined pathway.

Through new strategic partnerships with Brasfield & Gorrie, Ghafari Associates, Unity Health

Centers, and STERIS, we are bringing best-in-class expertise and technologies together into a

single, aligned delivery model—helping customers accelerate timelines, reduce complexity, and drive

operational performance from day one.

To learn more about Smith+Nephew's advanced solutions for orthopaedic reconstruction, please visit

Booth #839 at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans, LA

March 3-6, 2026 or visit www.smith-nephew.com

- ends –

References:

1. Bollars P, Janssen D, De Weerdt W, et al. Improved accuracy of implant placement with an

imageless handheld robotic system compared to conventional instrumentation in patients undergoing

total knee arthroplasty: a prospective randomized controlled trial using CT-based assessment of

radiological outcomes. Knee Surg Sports Traumatol Arthrosc. 2023;31(12):5446-5452.

2. Bollars P, Nathwani D, Albelooshi A, et al. Imageless handheld robotic-assisted total knee

arthroplasty showed better clinical outcomes than conventional total knee arthroplasty: A

randomized controlled trial with preliminary results at 1-year follow up. Knee.

2025;56(10):232-240.

3. Smith+Nephew 2025. Internal Report. 10158129

4. Smith+Nephew 2023. Internal Report 10092864 Ver A.7. I20-4GEN-A Verification Activity - TRIGEN

MAX Tibial Nail

5. Smith+Nephew 2023. Internal Report 10092852 Ver A. I20-4GEN-A Verification Activity - Screw

Prominence]

Media Enquiries

Gina Kamler

+1 (901) 262-9070

Smith+Nephew

gina.kamler@smith-nephew.com

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and

replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by

using technology to take the limits off living. We call this purpose ‘Life Unlimited'. Our 17,000

employees deliver this mission every day, making a difference to patients' lives through the

excellence of our product portfolio, and the invention and application of new technologies across

our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound

Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of

$6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 ((LSE:SN, NYSE:SNN). The terms

‘Group' and ‘Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated

subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X,

LinkedIn, Instagram or Facebook. For more information about Smith+Nephew, please visit

www.smith-nephew.com and follow us on LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For

example, statements regarding expected revenue growth and trading profit margins, market trends and

our product pipeline are forward-looking statements.

Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate",

"expect", "target", "consider" and similar expressions are generally intended to identify

forward-looking statements. Forward-looking statements involve known and unknown risks,

uncertainties and other important factors that could cause actual results to differ materially from

what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts

in Europe and the Middle East, economic and financial conditions in the markets we serve,

especially those affecting healthcare providers, payers and customers; price levels for established

and innovative medical devices; developments in medical technology; regulatory approvals,

reimbursement decisions or other government actions; product defects or recalls or other problems

with quality management systems or failure to comply with related regulations; litigation relating

to patent or other claims; legal and financial compliance risks and related investigative, remedial

or enforcement actions; disruption to our supply chain or operations or those of our suppliers;

competition for qualified personnel; strategic actions, including acquisitions and disposals, our

success in performing due diligence, valuing and integrating acquired businesses; disruption that

may result from transactions or other changes we make in our business plans or organisation to

adapt to market developments; relationships with healthcare professionals; reliance on information

technology and cybersecurity; disruptions due to natural disasters, weather and climate change

related events; changes in customer and other stakeholder sustainability expectations; changes in

taxation regulations; effects of foreign exchange volatility; and numerous other matters that

affect us or our markets, including those of a political, economic, business, competitive or

reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S.

Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended,

including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's

website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking

statement is based on information available to Smith+Nephew as of the date of the statement. All

written or oral forward-looking statements attributable to Smith+Nephew are qualified by this

caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking

statement to reflect any change in circumstances or in Smith+Nephew's expectations.

^◊Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026